Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer By Ogkologos - June 23, 2025 32 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer EMA Recommends Extension of Indications for Cabozantinib MOST POPULAR Speaking for Scotland: What our Scottish Campaigns Ambassadors want in a... August 24, 2022 Helping Kids Cope With Cancer: “Your Stories” Podcast January 11, 2021 5-Yr-Old Cancer Survivor Used His Birthday To Collect Toys For Sick... October 15, 2019 Six Months Immunogenicity of COVID-19 mRNA-based Vaccine in Patients with Actively... December 14, 2021 Load more HOT NEWS New on NCI Websites for June 2018 Prostate Cancer Study Finds Accelerated Partial-Breast Radiation Just as Effective as Whole Breast... Nirogacestat May Offer Hope to People with Desmoid Tumors
